The future of weight loss drugs may be less about the amount of weight lost and more about the frequency of injections. Pfizer and Amgen are developing monthly GLP-1 shots, a significant departure from the weekly injections of drugs like Wegovy and Zepbound. This shift aims to make weight loss drugs more convenient and easier to adhere to, addressing a common challenge faced by many patients. The development of these monthly injections is a response to the fact that the more frequently a medication must be taken, the more opportunities there are to miss doses or stop treatment altogether. This is particularly relevant for GLP-1 drugs, which typically require weekly doses due to their short half-life in the body. To overcome this, Pfizer and Amgen have engineered new drugs that remain active for longer periods, reducing the need for frequent injections. Pfizer's experimental drug, berobenatide, works by staying attached longer to a protein in the blood called albumin, which protects the molecule from being broken down too quickly. This has shown promising results in clinical trials, with patients losing up to 12.3% of their body weight on average. Amgen's monthly GLP-1 drug, MariTide, uses an antibody to prolong its stay in the body and is currently being tested in late-stage trials. The results from a mid-stage trial of MariTide found that it helped patients lose up to 20% of their body weight after 52 weeks, with side effects similar to other GLP-1 medications. The appeal of monthly injections is clear, especially for those who struggle with adhering to a strict dosing schedule. However, it's important to note that taking medication less frequently isn't always better. Some patients may prefer a weekly routine, and a gradual transition from weekly to monthly injections may be more effective. The development of these monthly GLP-1 drugs represents a significant advancement in the field of weight loss treatment, offering a more convenient and potentially more effective approach to managing obesity. As research continues, the future of weight loss drugs may indeed be less about the amount of weight lost and more about the ease and frequency of administration.
